Clinical trials: Malignant Melanomas
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external radiotherapy) patients with high risk of metastasis are randomized between: Adjuvant chemotherapy with Fotemustin.
- Trial name
- FOTEADJ (NCT02843386)
- Testing
- Adjuvant chemotherapy by Fotemustin, Intensive surveillance
- Where
- 6 sites in France, Switzerland
- Volunteers
- 302 people
- Sponsor
- Institut Curie
Melanoma
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- COMBI-AD (NCT01682083)
- Testing
- Dabrafenib, Trametinib
- Where
- 168 sites in United States, Argentina and 23 more
- Volunteers
- 870 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating…
- Conditions
- Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT02320305
- Testing
- MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Melanoma, Urothelial Carcinoma
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
- Trial name
- NCT05823246
- Testing
- QLF31907
- Where
- 6 sites in China
- Volunteers
- 66 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Melanoma, Merkel Cell Carcinoma
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Patients with melanoma, some other rare skin cancers, and some cancers of the penis and scrotum can have their cancer spread to the lymph nodes in the upper part of the leg, called the groin.
- Conditions
- Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma, Penile Carcinoma
- Trial name
- NCT01526486
- Testing
- Videoscopic procedure, Open, traditional approach
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Melanoma
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV…
- Trial name
- NCT05116202
- Testing
- Nivolumab, Ipilimumab, RO7247669 2100 mg
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted.
- Trial name
- NCT04658303
- Testing
- Pimonidazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yana Najjar
Metastatic Melanoma, Melanoma
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia.
- Trial name
- NCT07407166
- Testing
- Immunotherapy
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- Institute of Oncology Ljubljana
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02543645
- Testing
- Combination of Varlilumab and Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Celldex Therapeutics
Melanoma
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
- Trial name
- NCT04401995
- Testing
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diwakar Davar
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8
- Trial name
- DIET (NCT04645680)
- Testing
- Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
This study plans to test the pathologic complete response (pCR) rate of the combination biotherapy regimen consisting of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced but operable melanoma.
- Trial name
- NCT02736123
- Testing
- Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B
- Where
- United States
- Sponsor
- University of Pittsburgh
Melanoma
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma.
- Trial name
- NCT00130442
- Testing
- PI-88 and dacarbazine, dacarbazine or DTIC
- Where
- 12 sites in United States, Australia
- Volunteers
- 134 people
- Sponsor
- Cellxpert Biotechnology Corp.
Melanoma
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system.
- Trial name
- Mel62; 6PAC (NCT02385669)
- Testing
- Ipilimumab, 6MHP
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Craig L Slingluff, Jr
Malignant Melanoma, Metastatic
MRI and PET to Assess Pembrolizumab Response
The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron…
- Trial name
- MPAK (NCT02591654)
- Testing
- Pembrolizumab, FLT PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.